Patient, Tumor, and Treatment Characteristics
| Variable | Characteristic | Data |
| Sex | Male | 444 (56.8%) |
| Female | 338 (43.2%) | |
| Age (y) | 60.3 ± 11.0 (22–83) | |
| Location of primary tumor (n = 782) | Small intestine | 221 (28.3%) |
| Large intestine | 42 (5.4%) | |
| Lung | 60 (7.7%) | |
| Pancreas | 277 (35.4%) | |
| Unknown primary | 106 (13.6%) | |
| Other | 76 (9.7%) | |
| Tumor grade (n = 570) | Grade 1 | 182 (31.9%) |
| Grade 2 | 345 (60.5%) | |
| Grade 3 | 43 (7.5%) | |
| Ki-67 (n = 503) | Q1 | ≤2% |
| Q2 | 3%–5% | |
| Q3 | 6%–10% | |
| Q4 | >10% | |
| Functional tumor (n = 555) | Yes | 280 (50.5%) |
| No | 275 (49.5%) | |
| Performance status (n = 782) | WHO 0 | 547 (69.9%) |
| WHO 1 | 190 (24.3%) | |
| WHO 2–3 | 45 (5.8%) | |
| Comorbidities | Hypertension (n = 239) | 99 (41.4%) |
| Diabetes (n = 782) | 46 (5.9%) | |
| Prior treatment | Interferon-α (n = 727) | 36 (5.0%) |
| Chemotherapy (n = 727) | 159 (21.9%) | |
| Resection, primary tumor (n = 710) | 336 (47.3%) | |
| Ablation (n = 727) | 100 (13.8%) | |
| Radiotherapy (n = 727) | 35 (4.8%) | |
| Somatostatin analog (n = 727) | 297 (40.9%) | |
| Isotope (n = 782) | 177Lu | 295 (37.7%) |
| 90Y | 96 (12.3%) | |
| 177Lu and 90Y | 391 (50.0%) | |
| PRRT administrations (n = 782) | 3 | 395 (50.4%) |
| 4 | 329 (42.1%) | |
| 5–6 | 59 (7.5%) | |
| Cumulative activity (GBq) (n = 782) | 177Lu | 21.7 (13.3–36.7) |
| 90Y | 11.5 (4.8–23.6) | |
| 177Lu and 90Y | 18.2 (5.0–33.7) | |
| Blood count (n = 782) | Normal | 546 (69.8%) |
| CgA (n = 661) | Q1 | <112 |
| Q2 | 112–333 | |
| Q3 | 336–1,168 | |
| Q4 | >1,168 | |
| Serotonin (n = 627) | 273 (10–14,200) | |
| eGFR (n = 778) | 81.2 (30.56–259.08) | |
| Creatinine (n = 778) | 75.0 (27–186) |
Continuous data are mean ± SD followed by range. Categoric data are number followed by percentage. When variables are divided into quartiles, range of quartile is given. Percentages may not add up to 100% due to rounding.